Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease
Blood · 13.08.2026 · 148 (7) · 831-840
DOI: 10.1182/blood.2026033506 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 13.08.2026. Verfasst von Dian Zhou und 23 weiteren Autor:innen. Beteiligte Einrichtung: Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, B-Cell Maturation Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Patients with relapsed or refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) have inferior outcomes and lack effective therapies. We developed anti–B-cell maturation antigen (anti-BCMA)/G protein–coupled receptor, class C group 5 member D (GPRC5D) bispecific chimeric antigen receptors (CARs) to investigate the activity and safety of the CAR T cells in patients with extraosseous EMD. In this single-arm, open-label, phase 2 trial, we enrolled 37 patients with RRMM with extraosseous EMD, and anti-BCMA/GPRC5D bispecific CAR T cells were administered at 2.0 × 106 CAR T cells per kg. At a median follow-up of 10.1 months (interquartile range, 6.4-19.1), 36 of 37 patients (97%) obtained an overall response and measurable residual disease negativity, including 16 (43%) with stringent complete response. The median progression-free survival was 5.8 months (95% confidence interval, 2.2-9.4), and the median overall survival was not reached. The most common grade 3 or worse adverse events were hematologic toxicities (except lymphopenia; 37/37). Twenty-seven patients (73%) experienced cytokine release syndrome, all cases of which were grade 1 or 2. Two patients (5%) had grade 1 or 3 immune effector cell–associated neurotoxicity syndrome. These findings support that anti-BCMA/GPRC5D bispecific CAR T cells induced a high response rate in patients with RRMM with extraosseous EMD, and the safety profile was manageable. This ongoing trial is registered at www.clinicaltrials.gov as NCT05509530.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, China.
- Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated to Suzhou University, Changzhou, China.
- Department of Pediatrics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- YaKe Center for Cell Engineering and Therapeutics, Shanghai, China.
ORCID-Profile: Yuekun Qi, Xiaotian Zhang, Wei Chen, Feng Zhu, Yanlei Zhang, Wei Sang, Bin Pan
Zitieren
APA
Zhou, D., Qi, Y., Ma, S., Sun, Q., Gu, W., Xia, J., Zhang, X., Chen, W., Cheng, H., Qi, K., Zhu, F., Xia, F., Zhu, L., Li, H., Zhang, H., Yan, D., Qiu, T., Zhang, Y., Peng, S., …, & Yan, Z. (2026). Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease. Blood, 148(7), 831-840. https://doi.org/10.1182/blood.2026033506
Vancouver
Zhou D, Qi Y, Ma S, Sun Q, Gu W, Xia J, et al. Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease. Blood. 2026;148(7):831-840. doi:10.1182/blood.2026033506
BibTeX
@article{Zhou2026,
author = {Zhou, Dian and Qi, Yuekun and Ma, Sha and Sun, Qian and Gu, Weiying and Xia, Jieyun and Zhang, Xiaotian and Chen, Wei and Cheng, Hai and Qi, Kunming and Zhu, Feng and Xia, Fan and Zhu, Lili and Li, Hujun and Zhang, Huanxin and Yan, Dongmei and Qiu, Tingting and Zhang, Yanlei and Peng, Shuixiu and Sang, Wei and Li, Depeng and Chang, Alex H and Pan, Bin and Yan, Zhiling},
title = {Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease},
journal = {Blood},
year = {2026},
volume = {148},
number = {7},
pages = {831--840},
doi = {10.1182/blood.2026033506}
}
EUVIMED